TheiaNova Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Seed
  • (Upcoming)

  • Latest Deal Amount
  • $1.5M

  • Investors
  • 6

TheiaNova General Information

Description

Developer of regenerative eye drop therapies designed to treat vision disorders non-invasively. The company offers regenerative eye drops, corneal remodeling therapy, non-surgical vision treatments, ectatic disorder therapies, keratoconus treatments, and ophthalmic drug candidates, enabling patients with vision disorders to treat progressive conditions using non-invasive eye drops instead of surgery and restore corneal rigidity through collagen regeneration.

Contact Information

Website
www.theianova.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 205 Queen Street
  • Level 11, Tower One
  • Auckland, 1010
  • New Zealand
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 205 Queen Street
  • Level 11, Tower One
  • Auckland, 1010
  • New Zealand

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TheiaNova Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Seed Round $1.5M Upcoming Clinical Trials - General
4. Equity Crowdfunding Announced Clinical Trials - General
3. Early Stage VC 01-Oct-2026 Completed Clinical Trials - General
2. Angel (individual) 01-May-2026 Completed Clinical Trials - General
1. Accelerator/Incubator 18-Oct-2022 Completed Clinical Trials - General
To view TheiaNova’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

TheiaNova Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

TheiaNova Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024900917-A0 Ophthalmic methods Inactive 03-Apr-2024
JP-2023066425-A Ophthalmic composition and method of use thereof Active 05-Mar-2015
AU-2016226699-A1 Ophthalmic compositions and methods of use therefor Active 05-Mar-2015
AU-2016226699-B2 Ophthalmic compositions and methods of use therefor Active 05-Mar-2015
EP-3265096-A1 Ophthalmic compositions and methods of use therefor Active 05-Mar-2015 A61K38/1841
To view TheiaNova’s complete patent history, request access »

TheiaNova Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TheiaNova Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Booster Innovation Fund Venture Capital Minority
Flying Kiwi Angels Angel Group Minority
Auckland UniServices Corporate Venture Capital Minority
Bridgewest Group Venture Capital Minority
Bridgewest Ventures Accelerator/Incubator Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

TheiaNova FAQs

  • When was TheiaNova founded?

    TheiaNova was founded in 2022.

  • Where is TheiaNova headquartered?

    TheiaNova is headquartered in Auckland, New Zealand.

  • What is the size of TheiaNova?

    TheiaNova has 4 total employees.

  • What industry is TheiaNova in?

    TheiaNova’s primary industry is Drug Discovery.

  • Is TheiaNova a private or public company?

    TheiaNova is a Private company.

  • What is TheiaNova’s current revenue?

    The current revenue for TheiaNova is .

  • Who are TheiaNova’s investors?

    Booster Innovation Fund, Flying Kiwi Angels, Auckland UniServices, Bridgewest Group, and Bridgewest Ventures are 5 of 6 investors who have invested in TheiaNova.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process